Pipeline

Isarna has established a broad portfolio of next-generation first- and best-in-class antisense oligonucleotides blocking three key TGF-β variants with therapeutic potential across a range of indications. In ophthalmological indications, our compounds are clearly differentiated from the currently marketed anti-VEGF compounds such as Eylea and Lucentis and offer the potential for improved efficacy. Isarnahas started  Phase 2a development in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The approach has near-term upside potential through expanding the program into other key ophthalmology indications i.e., dry forms of age-related macular degeneration.

Indication /
Target
Research
Preclinical
Phase 1
Phase 2A
Phase 2B/3
Ophthalmology (TGF-B2)

nAMD/DME

dryAMD

Glaucoma Surgery

FIBROSIS/NASH

TGF-B1

ONCOLOGY

TGF-B2

TGF-B1

TGF-B3

TGF-B4

Clinical Trials

ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger RNA (mRNA) of TGF-β2. Preclinical studies have demonstrated that ISTH0036 is highly potent and shows selective target engagement (TGF-β2 mRNA and protein downregulation) consistent with long-lasting tissue uptake and pharmacodynamic effects.

Join Our Team

If you want to join a pioneering company developing life-changing medication, please contact us.

News & Events

Find out more about Isarna and be up-to-date with our News, Events & Press Releases.